Get the Stockscreener App
152.89
4.29%
-6.85
After Hours:
152.89
Charles River Laboratories International Inc stock is traded at $152.89, with a volume of 768.76K.
It is down -4.29% in the last 24 hours and up +0.09% over the past month.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
See More
Previous Close:
$159.74
Open:
$158.19
24h Volume:
768.76K
Relative Volume:
0.89
Market Cap:
$7.52B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
19.09
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-6.77%
1M Performance:
+0.09%
6M Performance:
-10.38%
1Y Performance:
-21.32%
1-Day Range:
$152.89
$158.80
1-Week Range:
$149.03
$167.50
52-Week Range:
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
152.89 | 7.54B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-23-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| May-14-25 | Upgrade | TD Cowen | Hold → Buy |
| May-08-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Logan Capital Management Inc. Has $1.74 Million Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Cinctive Capital Management LP Reduces Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories International (CRL) Expands Oncology Partnerships With PICI and CHLA - simplywall.st
Charles River Laboratories International (NYSE:CRL) Shares Gap UpWhat's Next? - MarketBeat
Charles River Laboratories International, Inc. Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer - MarketScreener
Charles River Collaborates to Advance Novel Oncology Research & Development - Contract Pharma
Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer - Business Wire
Gotham Asset Management LLC Increases Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Up 37.9% in August - MarketBeat
Transcript : Charles River Laboratories International, Inc. Presents at Baird Global Healthcare Conference 2025, Sep-10-2025 09 - MarketScreener
Dynamic Technology Lab Private Ltd Boosts Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Eminence Capital LP Sells 192,018 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Bought by Royal Bank of Canada - MarketBeat
A Closer Look at Charles River Laboratories (CRL) Valuation Following Key Cell Therapy Platform Enhancement - simplywall.st
Charles River Labs stock rating upgraded by Jefferies on DSA bookings improvement - Investing.com Canada
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold (CRL) - Seeking Alpha
This Thomson Reuters Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Evaluating Charles River Laboratories (CRL) Valuation Following New Cell Therapy Tech Integration - Yahoo Finance
CRL Stock Rating Upgraded to 'Buy' by Jefferies | CRL Stock News - GuruFocus
Charles River Laboratories International, Inc.'s (NYSE:CRL) Low P/S No Reason For Excitement - simplywall.st
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences - BioSpace
Charles River Laboratories to Present at Baird and Morgan Stanle - GuruFocus
What are the risks of holding Charles River Laboratories International Inc.July 2025 Update & Weekly High Conviction Ideas - beatles.ru
Ariel Investments LLC Purchases 33,449 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Is Charles River Laboratories International Inc. backed by strong institutional buyingTreasury Yields & Fast Exit and Entry Strategy Plans - beatles.ru
Canada Pension Plan Investment Board Buys 102,000 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
The Manufacturers Life Insurance Company Decreases Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
What’s the recovery path for long term holders of Charles River Laboratories International Inc.Profit Target & Consistent Profit Alerts - Newser
Measuring Charles River Laboratories International Inc.’s beta against major indicesMarket Trend Report & Risk Adjusted Buy/Sell Alerts - Newser
Published on: 2025-09-06 02:17:51 - خودرو بانک
Can Charles River Laboratories International Inc. lead its sector in growthTrade Exit Report & Expert Curated Trade Ideas - خودرو بانک
What are analysts’ price targets for Charles River Laboratories International Inc.July 2025 Levels & Free Weekly Watchlist of Top Performers - خودرو بانک
Why is Charles River Laboratories International Inc. stock going upWeekly Trend Recap & Stock Market Timing Techniques - خودرو بانک
Is Charles River Laboratories International Inc. likely to announce a buybackPortfolio Return Summary & Real-Time Volume Analysis - خودرو بانک
Is Charles River Laboratories International Inc. exposed to currency risks2025 Volatility Report & AI Enhanced Market Trend Forecasts - خودرو بانک
Sentiment analysis tools applied to Charles River Laboratories International Inc.2025 Performance Recap & Risk Managed Trade Strategies - Newser
How to read the order book for Charles River Laboratories International Inc.Market Growth Review & AI Driven Price Forecasts - Newser
Using AI based signals to follow Charles River Laboratories International Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Risk adjusted return profile for Charles River Laboratories International Inc. analyzed2025 Market Sentiment & Daily Profit Focused Screening - Newser
Leading vs lagging indicators on Charles River Laboratories International Inc. performanceJuly 2025 Volume & Verified High Yield Trade Plans - Newser
Tools to assess Charles River Laboratories International Inc.’s risk profilePortfolio Growth Summary & Stepwise Trade Execution Plans - Newser
Zacks Research Has Negative Estimate for CRL Q3 Earnings - MarketBeat
Does Charles River Laboratories International Inc. stock have upside surprise potentialJuly 2025 Outlook & AI Powered Market Trend Analysis - خودرو بانک
Applying Wyckoff theory to Charles River Laboratories International Inc. stock2025 Market Trends & Weekly Market Pulse Updates - Newser
Charles River Laboratories International Inc. stock trendline breakdownRecession Risk & Consistent Growth Stock Picks - Newser
Stock Analysis | Charles River Laboratories International OutlookMixed Signals Amid Diverging Analyst Views - AInvest
Strategies to average down on Charles River Laboratories International Inc.Earnings Recap Summary & Community Supported Trade Ideas - Newser
Is it the Right Time to Add CRL Stock to Your Portfolio Now? - sharewise.com
Risk vs reward if holding onto Charles River Laboratories International Inc.Earnings Risk Report & Fast Gain Swing Alerts - Newser
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):